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Advanced metastatic melanoma, one of the most 
aggressive skin malignancies, is currently without 
reliable therapy. The process of angiogenesis is crucial 
for progression and metastasis of the majority of solid 
tumors including melanomas. Therefore, new therapies 
are urgently needed. Mangiferin is a naturally occurring 
glucosylxanthone which exerts many pharmacological 
activities against cancer-inflammation. However, the 
effect of mangiferin on metastasis and tumor growth of 
metastatic melanoma remains unclear. In this study, we 
demonstrate that mangiferin interferes with inflammation, 
lipid and calcium signaling which selectively inhibits 
multiple NFkB target genes including interleukin-6, tumor 
necrosis factor, interferon gamma, vascular endothelial 
growth factor receptor 2, plasminogen activator urokinase, 
matrix metalloprotease 19, C-C Motif Chemokine Ligand 
2 and placental growth factor. This abrogates angiogenic 
and invasive processes and capillary tube formation of 
metastatic melanoma cells as well as human placental 
blood vessel explants in-vitro and blocks angiogenesis 
characteristic of the chicken egg chorioallantoic 
membrane assay and in melanoma syngeneic studies 
in vivo. The results obtained in this research illustrate 
promising anti-angiogenic effects of the natural 
glucosylxanthone mangiferin for further (pre)clinical 
studies in melanoma cancer patients. Melanoma Res XXX: 
000–000 Copyright © 2019 Wolters Kluwer Health, Inc. All 
rights reserved.
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Introduction
Skin cancer incidence is rapidly growing over the last 
decades, and melanoma represents one of the most 
aggressive and the deadliest forms. Current treatments 
include surgical resection, chemotherapy, photodynamic 
therapy, immunotherapy, biochemotherapy and targeted 
therapy. Despite the development of novel therapies, 
the management of malignant melanoma remains chal-
lenging [1]. The therapeutic strategy can include single 
agents or combined therapies, depending on the patient’s 
health, stage and location of the tumor [2]. The efficiency 
of these treatments can be decreased due to the develop-
ment of diverse resistance mechanisms. Various studies 
have shown the vascular angiogenic system to be pivotal 
for metastasis in melanoma. Angiogenesis, the develop-
ment of new blood vessels, from pre-existing vessels is a 
complex multifactorial process involved in tissue devel-
opment and wound healing but becomes pathologic 
when associated with solid tumor growth and metastasis 
[3]. Consequently, the effects of various anti-angiogenic 
experimental therapies are currently investigated in 
pre-clinical and clinical trials. Although most studies 
focus on inhibition of vascular endothelial growth factor 
(VEGF) signaling, others are aimed at determining the 
effect of multikinase inhibitors or the inhibition of angi-
ogenic integrin activity. However, overall survival rates 
have not significantly improved in different clinical trials 
with anti-angiogenic agents. Resistance to anti-VEGF 
monotherapy has been observed in several studies, espe-
cially in malignant melanoma [4–6]. Thus inhibition of a 
single kinase or a pathway is unlikely to stop malignant 
angiogenesis and metastasis. Therefore, new multi-tar-
geted approaches are urgently needed [7].
Mangiferin (1,3,6,7-tetrahydroxyxanthone-C2-β-D-glu-
coside) is a natural bioactive xanthonoid which can be 
purified from pulp, peel, seed, bark and leaf of many 
plant species, amongst which the mango tree (Mangifera 
indica L.), growing in most tropical areas of India, Africa, 
Asia and Central America. It has been cultivated in the 
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Indian subcontinent for over 4000 years in Ayurvedic and 
indigenous traditional medical systems and is chemical 
constituents are receiving a growing interest in the field 
of cancer research worldwide [8–12]. Today, mangiferin 
is known for its immunomodulatory [13,14], anti-tumoral 
[15,16], anti-inflammatory actions [17–20] and anti-ox-
idant actions [21,22]. Although a wide range of phar-
macological actions has already been documented, its 
anti-tumor mechanism of action related to neovasculari-
zation and migration of tumor cells has not yet been fully 
elucidated [9–12,23–25].
In the current study, we further characterize the poten-
tial anti-angiogenic action of mangiferin in melanoma 
and endothelial cell assays in vitro, the human placental 
blood vessel explant assay, the chicken egg chorioallan-
toic membrane (CAM) assay and in melanoma syngeneic 
studies in vivo. Furthermore, mangiferin specific gene 
expression changes in metastatic melanoma cells are ana-
lyzed by pathway analysis, related to cell migration, pro-
liferation, survival and vasculogenesis. Results are finally 
validated in an experimental in vivo model of angiogene-
sis using tumor necrosis factor (TNF) or a TNF-secreting 
melanoma syngeneic model as proangiogenic inducers, 
to evaluate inhibition of capillary tube formation and 
neovascularization by mangiferin. Altogether, we pro-
vide novel insights in the anti-angiogenic properties of 
the naturally occurring glucosylxanthone mangiferin for 
future therapeutic applications in metastatic melanoma.
Material and methods
Chemical and biological reagents
Mangiferin was purified and characterized from the aque-
ous extract of the bark of Mangifera indica L. to 95.5% 
purity at the Departments of Pharmacognosy, Institute of 
Food and Pharmacy, Havana University and Department 
of Analytical Chemistry of Center of Drugs Research and 
Development, CIDEM [15,26,27]. Recombinant FGF, 
TNF, VEGF were purchased from Peprotech (Neuilly/
Seine, France).
Cells for in-vitro assays
The EA.hy 926 hybridoma cell line of the human umbil-
ical vein endothelial cell with the human epithelial cell 
line A549, shown to retain several native endothelial cell 
characteristics, was cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum, 100 U/ml penicillin, 100 µg/ml streptomy-
cin and HAT selection supplement (Invitrogen, Carlsbad, 
California, USA) in mycoplasma- and endotoxin-free con-
ditions at 37°C with humidified 95% air/5% CO
2
 as pre-
viously described [28,29]. Microvascular endothelial cells 
were isolated by trypsinization from the dermal vessels of 
the vascular-rich region of the newborn human foreskin der-
mis obtained following routine circumcision as described 
previously [30,31]. The cells were cultured in MEM with 
10% fetal bovine serum, 100  U/ml penicillin, 100  µg/ml 
streptomycin in mycoplasma- and endotoxin-free condi-
tions at 37°C with humidified 95% air/5% CO
2
.
Metastatic B16 melanoma cells (B16F10 cell line) were 
routinely cultured in DMEM, supplemented with 10% 
fetal calf serum (FCS), 1% Penicillin/Streptomycin 
mixture (Pen/Strep, 10  000  IU/ml) and 2% HEPES 
[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] as 
previously described [29,32–34]. The cells were cultured 
by incubation at 37°C in a humidified 95% air/5% CO
2
 
atmosphere. Endothelial cells from human dermal micro-
vasculature were routinely cultured and characterized 
as described [30]. The cells were grown in MCDB-131 
medium supplemented with 10% FCS, 2  mM glu-
tamine, 100 U/ml penicillin and 100 μg/ml streptomycin. 
Culture medium and serum were obtained from BRL 
(Life Technologies, Carlsbad, California, USA). Cells 
were grown to confluence on plastic tissue culture flasks 
(COSTAR, Cambridge, Massachusetts, USA). All studies 
on endothelial cells were performed on early (up to the 
fifth passage) cultures that were 48–72 hours post conflu-
ent at the time of the study (long-confluent cells).
Cell viability assay
Cell viability was assessed by colorimetric assay using 
3-(4,5-dimethylthiozol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) (Sigma-Aldrich, St. Louis, Missouri, 
USA) as previously described [35]. Briefly, B16F10 mel-
anoma and EA.hy926 endothelial cells were plated into 
96-well plates and exposed to medium with/without man-
giferin (60, 120 and 240 μM) for 24 hours. Alternatively, 
primary endothelial cells from human dermal micro-
vasculature were grown for 1 week in medium supple-
mented with proangiogenic 10 ng/ml of basic fibroblast 
growth factor (bFGF) or 10 ng/ml of VEGF (Peprotech) 
in presence or absence of mangiferin, as indicated in fig-
ure legends. Following treatment, medium was refreshed 
and 10 μl of MTT reagent was added into each well and 
the plates were incubated at 37°C for 4 hours. Upon 
weak vortexing, the spectrophotometric absorbance was 
read on a microplate reader (BioRad Model 3550-UV, 
Hercules, California, USA) at 595  nm. Relative absorb-
ances in the linear range were converted into relative 
percent viable proliferating cells. Each individual experi-
ment was performed at least three times.
Western blot analysis
Following treatment, cells were lysed for 15 minutes 
in 150  mM NaCl, 1  mM EGTA, 1  mM EDTA, 1  mM 
ß-glycerolphosphate, 1% Triton X-100 (w/v), 20  mM 
Tris HCl, pH = 7.5 and proteinase inhibitor (Complete, 
EDTA-free Protease Inhibitor Cocktail; Sigma-Aldrich) 
plus PhosphataseArrest Phosphatase Inhibitor Cocktail 
(phosphataseArrest; G-Biosciences, St. Louis, Missouri, 
USA). Then, cells were centrifuged for 15 minutes at 
13 200g at 4°C, and supernatant containing the soluble 
proteins were stored at −20°C until Western analysis. 
Subsequently, protein lysates (20  µg) were mixed with 
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5× sample buffer (5% SDS, 20% glycerol, 0.2% bromo-
phenol-blue, 250  mM DTT, 65  mM Tris HCl) all pur-
chased from Sigma Aldrich, heated for 5 minutes at 95°C 
and loaded in a 12% SDS-PAGE gel. Proteins contained 
in the homogenates were separated during 30 minutes at 
60–70 V and 1 hour at a constant voltage of 130 V. Further 
10 μl of BenchMark Pre-Stained Protein Standard (Life 
Technologies, California, USA) were also loaded next to 
the samples. After separation proteins transferred onto 
a Nitrocellulose Membrane (BioRad, California, USA) 
during 2 hours at 45 V. Non-specific binding sites were 
blocked by incubating the membranes with blocking 
buffer (0.05 % Tween 20, 1 × TBS, 5% BSA) for 1 hour at 
room temperature. The membrane was then incubated 
with the primary antibodies: rabbit mAb anti-Phospho-
NF-κB p65 (Ser536) (#3031; Cell Signaling Technology, 
Danvers, Massachusetts, USA) or rabbit polyclonal Anti-
GAPDH antibody (ab9485; Abcam, Cambridge, UK) 
overnight at 4°C. After membranes were washed they were 
incubated with (1:10 000) Donkey anti-Rabbit IgG (H + L) 
Secondary Antibody-HRP (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) for 1 hour at room temper-
ature. Chemiluminiscence detection was performed using 
the ECL detection kit (Pierce ECL Western Blotting 
Substrate; Thermo Fisher Scientific) in a ChemiDoc MP 
system (BioRad, Hercules, California, USA).
Cell scratch migration assay
Wound healing assay was carried out to determine the 
cell migration ability of human endothelial cells. The 
wound healing migration assay was performed as previ-
ously described [36,37]. Briefly, B16F10 and EAhy926 
cells were plated on 6-well plates (Corning, New York) 
and grown to 80%–90% confluence. A sterilized 200  μl 
pipette tip was used to generate a scratch ‘wound’across 
the cell monolayer, and the plates were washed with PBS. 
The cells were cultured in DMEM medium containing 
concentrations of Mangiferin (60, 120 and 240  μM) for 
24 hours at 37°C. Control cells were cultured in medium 
alone. The untreated and treated cells were stimulated 
with bFGF (10 ng/ml) to evaluate the effects on migra-
tion induction. Next, the cells were washed briefly, fixed 
with absolute methanol, and then stained with 2% crys-
tal violet solution [38]. Images from the region of the 
monolayer adjacent to the wound into which cells had 
migrated were taken with a camera attached to a bright-
field microscope (Olympus, Hamburg, Germany). Three 
randomly selected views along the scraped line were 
photographed on each well at a magnification of 100×. A 
reduction in the wounded area is indicative for increase 
in cell motility. The experiments were performed in trip-
licate at different mangiferin doses (n = 3).
Human placental blood vessel explant assay
Superficial vessels, approximately 1–2  mm in diameter 
and 2–5 cm in length, were excised from the apical sur-
face of human placentas within 24 hours of an elective 
cesarean birth [39]. The vessels were placed in Hank’s 
balanced salt solution containing 2.5 μg/ml of fungizone 
and cut into 1–2 mm fragments using fine dissecting 
forceps and iridectomy scissors. Vessel fragments were 
free of residual clots and soaked in Hank’s balanced salt 
solution before use. Dissecting and sectioning of vessels 
was performed with the aid of a magnifying lens. Assays 
were performed in 48-well culture plates (COSTAR). 
Fifteen microliters of thrombin (50 NIH U/ml in 0.15 M 
NaCl) was added to each well, followed by 0.5 ml/well 
of 3  mg/ml fibrinogen (bovine plasma; Calbiochem-
Novabiochem Corporation, La Jolla, California, USA) in 
Medium 199 (Gibco, Paisley, Scotland). The thrombin 
and fibrinogen were mixed rapidly, and one vessel frag-
ment was quickly placed in the center of the well before 
clot formation. Fibrin gel formation usually occurred 
within 30 seconds, and ideally, the vessel fragment 
remained suspended in the gel [40]. After gel formation, 
0.5  ml/well of medium 199 supplemented with 10% 
FCS, 2 mM glutamine, 100 U/ml penicillin and 100 μg/
ml streptomycin were added. Vessels were cultured at 
37°C in a humidified environment for 14–21 days, and 
the medium was changed twice weekly. Angiogenesis 
was quantified by computer-based image analysis using 
the Image 1.41 software (National Institutes of Health, 
Bethesda, Maryland, USA); digital images of the cultures 
were obtained with a Dycam 3.04 digital image cam-
era (Dycam Inc., Chatsworth, California, USA). To test 
the angiogenesis modulating activity, mangiferin (20–
200 μM) was diluted in Medium 199. Immediately after 
the embedding of vessel fragments in the fibrin gels, 
0.5 ml of the medium containing the test substance was 
added to each well, and each treatment was performed 
in quadruplicate. Fresh medium containing test sub-
stance was added twice weekly. Control cultures received 
medium without mangiferin. Basic FGF (0.5 ng/ml) was 
used as promoter. In addition, each well-received 5 μg/ml 
of aprotinin which was added to prevent fibrinolysis by 
the vessel fragments.
Capillary tube formation by endothelial cells 
sandwiched between fibrin gels
Capillary tube formation was assessed essentially as 
previously described [41]. Fibrinogen (bovine plasma; 
Calbiochem-Novabiochem Corporation) was used at a final 
concentration of 1–3 mg/ml. To make the underlying fibrin 
gel, 225 μl of fibrinogen solution was placed into each well 
of a 24-well culture plate and human thrombin (10–30 U/
ml in 10 × minimum essential medium) was added to a final 
concentration of one unit of thrombin/mg of fibrinogen. 
After fibrin gel polymerization (at least 5 minutes at 37°C), 
1 ml aliquots of microvascular cells (250 000 cells/ml) sus-
pended in serum-free MCDB-131, supplemented as indi-
cated above, were seeded onto each gel. After formation of 
a confluent monolayer (24 hours after seeding), the culture 
medium was aspirated and the same procedure was used 
to generate a second fibrin gel overlying the apical surface 
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of the cells. After 5 minutes of polymerization at 37°C, 
1  ml aliquots of supplemented, serum-free MCDB-131 
were added to each well and tube formation was assessed. 
The dimensions (length in mM) of each capillary tube as 
a signal of the angiogenic process were quantified by com-
puter-based image analysis using the Image 1.41 software 
(National Institutes of Health, Bethesda, Maryland, USA). 
Digital images of the cultures were obtained with a Dycam 
3.04 digital image camera (Dycam Inc.).
Chorioallantoic membrane angiogenesis assay
This assay was performed as described previously [42]. 
Briefly, fertilized eggs were incubated for 3 days at 37 °C 
with a humidity of 48%. On day 4, albumen was removed 
to detach the shell from the developing CAM, and a win-
dow was made in the eggshell, exposing the CAM, and cov-
ered with a breathing film (Suprasorb F). The eggs were 
returned to the incubator until day 10, before application 
of the test compounds. Test compound (Mangiferin 50 μg/
disc; bFGF 2  μg/ml) and control (DMEM without 10% 
FBS) were poured onto separate sterile discs (12 mm diam-
eter), which were allowed to dry under sterile conditions. 
A solution of cortisone acetate (125  μg/disc) was poured 
onto all discs to prevent an inflammatory response. Test 
discs probed with recombinant human bFGF (Peprotech) 
served as a control for angiogenesis stimulation. On each 
CAM, the disc containing control compound and the disc 
containing test compound were placed at a distance of 1 cm. 
The windows were covered and the eggs were incubated 
until day 14, before assessment of angiogenesis. Therefore, 
the eggs were flooded with 10% buffered formalin and the 
eggs were kept at room temperature for at least 20 minutes. 
The CAM, the area of the discs included, was placed in 
a petri dish with 10% buffered formalin. The plastic discs 
were removed and phase-contrast pictures of the area of 
the plastic discs were taken. The vascular index was meas-
ured as described [42]. Vascular intersections on a grid con-
taining three concentric circles (6, 8 and 10 mm diameter 
with as center the center of the disc) were counted. The 
angiogenic index = t/c, with t the number of intersections 
in the area covered by the test disc and c the number of 
intersections in the area covered by the control disc in the 
same egg. Photographs of each disc were taken in each 
experimental condition in order to determine the level of 
vascularization that has occurred in each case.
RNA extraction and Angiogenesis RT2 Profiler PCR 
Array (PAMM-024Z)
Total RNA from non-treated controls and mangifer-
in-treated murine melanoma B16F10 cells from three 
independent experiments was isolated using 1  ml of 
TRI Reagent (Sigma-Aldrich) per 5 × 106 cells and fur-
ther proceeded according to the manufacturer’s proto-
col till the step of phase separation. After transferring 
the aqueous phase to a new 1.5 ml microtube, an equal 
amount of 70% ethanol was added and samples were fur-
ther purified on RNeasy spin columns (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. 
Following extraction concentration was measured by 
nanodrop (NanoDrop 1000; Thermo Scientific, Waltham, 
Massachusetts, USA). The Mouse Angiogenesis RT2 
Profiler PCR Array (PAMM-024Z) (SABiosciences; 
Qiagen) was used to determine the expression levels 
of 84 key genes involved in angiogenesis, essentially as 
previously described [43]. One microgram of total RNA, 
treated with RNase-Free DNase Set (Qiagen), was used 
for further processing according to the manufacturer’s 
protocol. cDNA synthesis was performed by RT2 First 
Strand Kit (C-03). The RT2 SYBR Green ROX qPCR 
Mastermix was used for preparing the experimental cock-
tail according to the protocol and 25 µl was dispensed to 
each well of 96-well PCR Array plate. Relative mRNA 
levels of genes of interest were quantified by real-time 
quantitative PCR reaction on an ABI Prism 7300 (Applied 
Biosystems, Carlsbad, California, USA) and normalized 
against selected housekeeping genes (HPRT, ACTB). An 
Excel-based RT2 Profiler PCR Array Template (V3.3) 
(http://www.sabiosciences.com/pcrarraydataanalysis.php) 
was used for statistical analysis (paired T-test) and fold 
change quantification of the samples treated with man-
giferin as compared to DMSO controls. A gene was con-
sidered not detectable when Ct > 35. Moreover, Ct was 
defined as 35 for the ΔCt calculation when the signal was 
under detectable limits. Fold-change and fold-regulation 
values >2 were indicative of upregulated genes; fold-
change values <0.5 and fold-regulation values <−2 were 
indicative of downregulated genes.
Ingenuity pathway analysis
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems) 
was used for functional enrichment and detection of signif-
icant pathways. The principal algorithm/method embed-
ded in IPA for biological functions/pathway enrichment. 
Briefly, the program searches through the list of selected 
genes and determines genes which are involved in the 
respective Knowledge Base (including GO term, canon-
ical signal transduction or metabolic pathways). Then, 
Fisher’s Exact algorithm is used to calculate the proba-
bility of which each functional gene set is enriched. Only 
the biological functions/pathways (Bonferroni’s corrected 
P-value <0.05) were considered significantly enriched. 
The activation or inhibition status of the functions/
pathways was predicted using IPA Upstream Regulator 
Analysis Tool by calculating a regulation Z-score and an 
overlap P-value, which is based on the number of known 
target genes of interest pathway/function, expression 
changes of these target genes and their agreement with 
literature findings. Pathways were considered signifi-
cantly inhibited (−3 <Z-score <−0,5) or activated (0.5> 
Z-score >3) with an overlap P-value ≤0.05. The detailed 
descriptions of IPA analysis are available under ‘Upstream 
Regulator Analysis’, ‘Biological Functions Analysis’ and 
‘Ingenuity Canonical Pathways Analysis’ on the IPA web-
site (http://www.ingenuity.com) [44].
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In-vivo studies
Male 6–8-week-old C57BL/6 mice were purchased from 
the National Center for Animal Breeding (CENPALAB), 
Havana, Cuba. Animal was acclimated (25 ± 1°C) and 
caged in groups of five. They received a chow diet and 
water ad libitum. Animals were anesthetized in a meth-
oxyflurane chamber before the experimental procedure 
and were observed until fully recovered. They were sac-
rificed by a lethal dose of methoxyflurane. All the exper-
iments were carried out in compliance with the Ethical 
Standards for Animal Experimentation of the Institute 
of Pharmacy and Food of the University of Havana. 
The inhibitory activity of mangiferin against tumor 
necrosis factor-α (TNF-α) -induced angiogenesis was 
determined using matrigel (Becton Dickinson, Franklin 
Lakes, New Jersey, USA), an extract of murine basement 
proteins from the Engelbreth-Holm-Swarm mouse sar-
coma consisting predominantly of laminin, collagen IV, 
heparan sulfate, proteoglycan and nidogen/entactin. The 
sterile solution of Matrigel was prepared as previously 
described [45]. Briefly, 500 μl of Matrigel with 64 U/ml of 
heparin (Sigma-Aldrich) and 10 ng/ml of TNF-α (from 
Sigma-Aldrich) were injected subcutaneously (s.c.) into 
the abdomens of mice. A week later, angiogenesis was 
examined macroscopically and the content of hemo-
globin in the gels was determined using the Drabkin 
method and Drabkin reagent kit 525 (Sigma-Aldrich) 
[46]. In the same conditions, other in vivo assay was per-
formed using as inductor of neovascularization B16F10 
(105/ml) melanoma cells line as described [47]
Statistical analysis
The results are presented as mean ± SD or SEM as indi-
cated and statistical significance between the groups 
was determined by one-way analysis of variance and 
Dunnett’s multiple comparison post-test. All statistical 
analyses and figures were carried out using GraphPad 
Prism Version 7.00. P values less than 0.05 (P < 0.05) was 
considered significant.
Results
Mangiferin inhibits motility of metastatic B16F10 
melanoma and human EA.hy926 endothelial cells
We examined the ability of mangiferin to interfere 
with cellular migration of human metastatic melanoma 
B16F10 and EA.hy926 endothelial cells using a classic 
in vitro wound healing in-vitro model. Confluent mon-
olayers of B16F10 and EA.hy926 cells were scratched 
with a 200 μl yellow tip and the cell migration into the 
wound from adjacent areas of the monolayer was evalu-
ated following different treatments. The cells were left 
untreated or treated for 24 hours with mangiferin in the 
presence or absence of bFGF to promote motility. As 
shown in Fig. 1, mangiferin treatment reveals significant 
inhibitory effects on bFGF-induced cellular migration of 
B16F10 (Fig. 1a) and EA.hy926 (Fig. 1b) cells.
Mangiferin does not affect cell viability of B16F10 
melanoma and human EA.hy926 endothelial cells
Next, we evaluated potential cytotoxic effects of increas-
ing concentrations of mangiferin treatment (24 hours) in 
B16F10 and EA.hy926 endothelial cells in an MTT cell 
viability assay. No significant cell cytotoxic effects could 
be observed in a concentration range of 30–240 μM man-
giferin, whereas cell viability was significantly reduced to 
5%–10% in presence of the reference cytotoxic anti-can-
cer compound withaferin A (10 μM) (Fig. 2a and b) [43],
Mangiferin inhibits proangiogenic cell proliferation of 
primary endothelial cells
Next, we evaluated effects of increasing concentrations 
of mangiferin treatment on primary human dermal micro-
vasculature endothelial cells in presence of a proangio-
genic stimulus, that is, bFGF (10 ng/ml) or VEGF(10 ng/
ml) in a cell viability MTT assay. Our results in Fig. 2 
show that mangiferin dose dependently inhibits bFGF 
as well as VEGF stimulated endothelial cell growth in a 
concentration range of 30–120 µM (Fig. 2c and d).
Mangiferin inhibits capillary growth and tube formation 
in the human placental blood vessel explant assay and 
endothelial fibrin gel sandwich assay
Fragments of human placental blood vessel were embed-
ded in fibrin gel with mangiferin to evaluate mangiferin 
effects on capillary growth. As can be seen in Fig.  2e, 
mangiferin dose dependently (30–240  μM) inhibits 
bFGF (0.5 ng/ml) induced capillary growth with a max-
imal inhibition of 50% at 240 μM mangiferin. Similarly, 
capillary tube formation by primary endothelial cells 
sandwiched between fibrin gels was dose dependently 
inhibited by mangiferin in a similar human anti-angio-
genic in-vitro assay (Fig. 2f) with a maximal inhibition of 
70 % at 240 μM.
Mangiferin selectively inhibits IL6, TNF, IFNG, 
KDR(VEGFR2), PLAU, MMP19, CCL2 and PGF gene 
expression
We performed QPCR to evaluate the ability of 6 hours 
mangiferin treatment to modulate gene expression of 84 
selected genes on the angiogenesis PCR array (Qiagen) 
in B16F10 cells. Of special note, only nine genes revealed 
significant inhibition (>2-fold change, P < 0.05), whereas 
most other genes remained unaffected (Fig. 3a and data 
not shown), irrespective of the observed variation in basal 
expression of the different genes (Fig. 3b).
Mangiferin decreased gene expression strongly inhibits 
angiogenesis, cell proliferation, cell motility (invasion, 
migration) and cell viability through upstream 
inhibition of calcium signaling, lipid metabolism and 
inflammatory pathways (NFkB, HMGB1, NO)
IPA core analysis of the list of genes which are signifi-
cantly inhibited upon mangiferin treatment in B16F10 
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Fig. 1
Mangiferin inhibits bFGF-dependent migration of metastatic melanoma and endothelial cells. B16F10 melanoma (a) and EA.hy926 endothelial 
(b) cells were left untreated (UT) or treated with solvent (S, 0.1% DMSO control) or Mangiferin (Mg, 240 µM) in presence or absence of bFGF 
(10 ng/ml). The migratory cells were stained with crystal violet and photographed at 0 and 24 hours, as indicated.
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cells (>2-fold change, P < 0.05) confirms highly significant 
enrichment (10−4 < P-value <10−12) of pathways related 
to angiogenesis, cell proliferation, cell motility (invasion, 
migration) and cell viability (Fig. 4a). Moreover, Z-score 
analysis shows moderate to strong inhibition of these bio-
logical processes (Fig. 4b), in line with our in-vitro cell 
Fig. 2
Mangiferin lacks cellular cytotoxicity and inhibits proangiogenic endothelial cell proliferation and capillary tube growth. (a) Viability of B16F10 
melanoma cells in presence of increasing concentrations [of mangiferin (24 hours treatment, Mg: 30, 60, 120 and 240 µM as indicated)] was 
evaluated in a MTT cell viability assay. As a positive control for cytotoxicity, the reference anti-cancer compound withaferin A was included. As a 
positive control for cytotoxicity, the reference anti-cancer compound withaferin A was included. Each group represents the mean ± SEM of three 
assays ****P < 0.0001, **P < 0.01 and *P < 0.05 compared with control value. (b) Viability of EA.hy926 endothelial cells in presence of increas-
ing concentrations of mangiferin (24 hours treatment, Mg: 30, 60, 120 and 240 µM as indicated) was evaluated in a MTT cell viability assay. As a 
positive control for cytotoxicity, the reference ant-cancer compound withaferin A was included. Each group represents the mean ± SEM of three 
assays ****P < 0.0001, **P < 0.01 and *P < 0.05 compared with control value. (c and d) Human dermal microvascular endothelial cells were 
left untreated (Control) or treated with proangiogenic stimuli bFGF (10 ng/ml) (c) and VEGF (10 ng/ml) (d), either or not upon cotreatment with 
different concentrations of mangiferin (Mg: 30, 60 and 120 µM as indicated). Results are presented as relative cell number (% living cells). Each 
group represents the mean ± SEM of three assays. *P < 0.05 compared with bFGF or VEGF cell stimulation. (e) Inhibitory effects of mangiferin 
(Mg, 30–240 µM) on capillary growth and tube formation on ex-vivo explants of human placental blood vessel stimulated with bFGF (0.5 ng/ml) in 
an endothelial fibrin gel sandwich assay. Values are expressed as percentage of inhibition of new blood vessel formation respect to control group. 
Each group represents the mean ± SEM of three assays. *P < 0.05 and **P < 0.01 compared with bFGF control setup. (f) Effect of mangif-
erin (Mg, 30–240 µM) against capillary growth and tube formation by endothelial cells sandwiched between fibrin gels. Each group represents 
the mean ± SEM. of 10 cultures. **P < 0.01 and *P < 0.05 compared with control value. bFGF, basic fibroblast growth factor; VEGF, vascular 
endothelial growth factor.
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assay results. Of special note, upstream analysis predicts 
significant inhibition of NFkB signaling (Fig. 4b), which 
could be experimentally validated by Western analy-
sis, revealing dose-dependent inhibition of NFkB p65 
Ser536 phosphorylation in response to Mangiferin, to a 
similar extent as the reference NFkB inhibitor Withaferin 
A (Fig. 5) [48,49].
Mangiferin inhibits basal and fibroblast growth factor 
induced angiogenesis in the chorioallantoic membrane 
assay
Angiogenesis is an attractive target in cancer therapy not 
only because it supplies oxygen and nutrients for the sur-
vival of tumor cells but also provides the route for meta-
static spread of these cancer cells. To investigate possible 
Fig. 3
Modulation of angiogenesis pathway-related gene expression by Mangiferin in B16F10 melanoma cells. B16F10 melanoma cells were left 
untreated (0.1% DMSO control) or treated for 6 hours with 240 µM Mangiferin (Mg). Upon RNA isolation, gene expression of 84 known or 
predicted genes involved in angiogenesis was determined by QPCR array. Pairwise mRNA changes of the 84 genes were calculated according to 
the ΔCt method and normalized against selected housekeeping genes (HPRT, ACTB) with the Excel-based RT2 Profiler PCR Array Template (see 
Methods section). (a) Bargraph summarizes most significant gene expression changes upon mangiferin treatment (relative fold change to control 
setup), in addition to various genes which remain unaffected. Significantly inhibited genes are marked with asterisks, **P < 0.01 and *P < 0.05.  
(b) Bar graph represents relative basal gene expression levels of the different genes presented in panel A.
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mechanisms of mangiferin action against neovasculariza-
tion in vivo, we evaluated potential anti-angiogenic effect 
of mangiferin in the CAM assay involving the coordination 
and integration of multicellular responses during develop-
ment of the chick embryo. As shown in Fig. 6a, no vascu-
lar sprouting was observed when CAM was treated with 
Fig. 4
Ingenuity pathway analysis of mangiferin specific transcriptome changes in B16F10 cells. (a) Disease function related pathway enrichment 
analysis of mangiferin responsive genes (-log P-value). (b) Z-scores of IPA enriched pathways, disease functions and/or upstream regulators. IPA, 
ingenuity pathway analysis.
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serum-free medium (control). However, vascular sprout-
ing was observed in the CAM assay upon treatment with 
bFGF (2 μg/ml), which could be strongly reversed upon 
cotreatment with mangiferin (50 μg/disc), in line with the 
in-vitro cell assays. Corresponding quantitative data from 
the CAM assay images are summarized in Fig. 6b, which 
show that bFGF (2 μg/ml) increases the angiogenic index 
with 40% as compared to the control setup. Moreover, 
Mangiferin (50 μg/disc) completely inhibits the formation 
of new blood vessels induced by bFGF (Fig. 7b).
Mangiferin inhibits tumor necrosis factor induced 
neovascularization in vivo
To further validate anti-angiogenic effects of mangiferin 
in an in-vivo mouse model, the proangiogenic cytokine 
TNF [50] was mixed with matrigel and heparin, and 
injected into the dorsal region of C57BL/6 mice to pro-
mote angiogenesis. The hemoglobin content of the gels, 
calculated by Drabkin’s method, was well correlated 
with the number of new vessels formed. In line with 
our in-vitro results, we found that mangiferin (120 and 
240  μM), dose dependently inhibited TNF-induced 
angiogenesis (Fig.  7a). Similarly, when TNF treatment 
was replaced by xenografts of TNF producing metastatic 
B16F10 melanoma cells (105 cells/ml), we demonstrate 
that 120 and 240 μM treatment similarly inhibit B16F10 
tumor cell-induced angiogenesis (Fig. 7b).
Discussion
The process of angiogenesis is crucial for progression 
and metastasis in melanoma. Angiogenesis is character-
ized by increased microvessel endothelial cell prolifera-
tion, production and/or activation of matrix degradative 
enzymes, migration in the subendothelial matrix and dif-
ferentiation into functional new capillaries [51]. As such, 
angiogenesis relies on interplay of multiple genes and 
anti-angiogenic therapies may require a multi-targeted 
approach [7]. Various plant-derived polyphenols, that is, 
constituents of green tea, catechins and gallic acid deriva-
tives already showed ‘promiscuous’multitargeted inhibi-
tion of several key events of the angiogenic process such 
as proliferation and migration of endothelial cells [7,52].
Here we further demonstrate by different in-vitro and 
in-vivo approaches that mangiferin, a natural glycosylated 
xanthone isolated from Mangifera Indica, potently 
inhibits bFGF- and TNF-dependent cell migration 
and angiogenesis as well as microvessel outgrowth and 
Fig. 5
Mangiferin inhibits basal NFkB p65 Ser536 phosphorylation in 
B16F10 cells. B16F10 cells treated for 6 hours with Mg (60, 120, 
240 µM as indicated) or the reference NFkB inhibitor Withaferin A 
(2, 5, 10 µM as indicated) Total cell lysates were prepared in SDS/
Laemmli sample buffer and extracts were analyzed for changes in 
NFkB activation via expression levels of phospho-NFkB p65 Ser536. 
Equal protein loading is verified by Western analysis of corresponding 
GAPDH expression levels.
Fig. 6
Mangiferin inhibits bFGF induced neovascularisation in the chorioallantoic membrane (CAM) assay. Mangiferin (Mg) was evaluated in a chicken 
CAM assay as an in-vivo model of angiogenesis. Representative photographs of each disk are shown in (a), where it is possible to appreciate the 
degree of vascularization that occurs with each experimental condition used. The arrow indicates areas of very high vascularization induced by 
FGF and areas of very low vascularization due to the anti-angiogenic effect of mangiferin. The Angiogenic index = (t − c)/c in CAM angiogenesis 
assay, was determined as described in materials and methods. Bars indicate angiogenic indices (%) of CAMs probed with serum-free medium. 
Conditions evaluated: bFGF (2 µg/ml), Mangiferin (Mg) 50 µg/disc/egg. Data represents mean ± SD. In each experiment, seven eggs were tested 
per each condition. The Mann–Whitney U-test was used for statistical analysis (***P < 0.001, statistically different from the mean angiogenic index 
of CAMs bFGF setup, which promotes vascularization). bFGF, basic fibroblast growth factor.
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neovascularization. Along the same line, PCR array gene 
expression profiling revealed that mangiferin selectively 
inhibits expression of IL6, TNF, IFNG, KDR(VEGFR2), 
FGF1, PLAU, MMP19, CCL2 and placental growth 
factor (PGF), to block angiogenesis, metastasis-inva-
sion-motility, cell proliferation and viability in cancer 
signaling processes, according to IPA pathway enrich-
ment analysis. Along the same line, other phytochemi-
cals such as ferulic acid and kaempferol were also found 
to inhibit angiogenesis in part through inhibition of 
FGF1 [53] and PGF expression [54]. Furthermore, the 
multi-tyrosine kinase inhibitor anlotinib was found to 
suppress blood vessels sprouting, reduce microvessel 
density and endothelial migration and tube formation 
upon inhibition of KDR(VEGR2)-induced angiogen-
esis, in analogy to mangiferin [55,56]. Moreover, cell 
invasiveness in angiogenesis involves various extracel-
lularly acting proteolytic enzymes, including essentially 
MMPs (e.g. interstitial collagenases, gelatinases and 
stromelysins) and serine proteases, in particular the PA/
plasmin system [52]. In line with this model, our results 
demonstrate a clear inhibition of MMP19 and PLAU 
protease gene expression by mangiferin, which may 
further decrease protein levels and protease functions 
[57–60]. With respect to the pro-metastatic role of IL6, 
various reports demonstrate that therapeutic inhibition 
of IL6/Stat3 signaling by natural compounds strongly 
reduces cell motility and invasive cancer properties of 
melanoma cells [43,61–64]. However, metastasis is fre-
quently caused by a mix of tumor-derived cytokines and 
chemokines in the microenvironment, such as IL6, TNF 
or CCL2 [50,65,66]. Finally, in line with previous results 
obtained in our lab and of others [15,67], bioinformatic 
IPA analysis suggests that mangiferin inhibits NFkB 
signaling in metastatic melanoma cells, which could be 
experimentally confirmed by Western analysis showing 
similar inhibition of phosphoactivated NFkB p65 Ser536 
as the reference NFkB inhibitor Withaferin A [48,49]. In 
addition to NFkB inhibition, epigenetic modulation of 
DNA methylation, histone marks or noncoding RNAs 
in response to mangiferin may further fine-tune gene 
selective transcription [68,69]. Of particular interest, 
prediction of upstream regulators also indicates mangif-
erin dependent regulation of calcium signaling, which is 
critically involved in angiogenic VEGF signaling [70,71]. 
Important roles for HMGB1 and mir15 have also been 
described in angiogenesis, which deserves further molec-
ular investigation [72,73].
In conclusion, although modern targeted therapies have 
ameliorated the management of metastatic melanoma, 
safer, more affordable and more effective strategies for 
treatment of skin cancer patients are needed. We demon-
strate that mangiferin hold promise as a novel drug phar-
macophore candidate for cancer treatment in the battle 
against melanoma, as this glucosylxanthone exerts potent 
anti-angiogenic and metastatic effects and is widely avail-
able, highly tolerated and cost-effective. Further inter-
vention studies and (pre)clinical trials are needed for 
further development into cancer therapeutic applications 
for melanoma patients.
Fig. 7
Mangiferin inhibits neovascularisation in vivo. Effects of mangiferin (Mg, 60–240 µM) on (a) TNF- and (b) B16F10 (105 cells)-induced angio-
genesis in mouse abdominal subcutaneous connective tissue. TNF-α (10 ng/ml) or B16F10 cells (105 cells/ml) were mixed with 64 U/ml of 
heparin, 0.5 ml of matrigel and mangiferin. These mixtures were injected subcutaneously into the abdominal midline of mice. Data represent the 
mean hemoglobin values (determined by Drabkin’s method) from at least five mice per point with SEM as indicated. Statistical differences among 
groups were analyzed by one-way ANOVA and Dunnett’s multiple comparison test (*P < 0.05 and **P < 0.01). ANOVA, analysis of variance; TNF, 
tumor necrosis factor.
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